APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

10 يوليو 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 يوليو 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

07 يونيو 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 يونيو 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS

25 مايو 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 مايو 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results

04 مايو 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference

03 مايو 2023 06:00:01 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results

27 أبريل 2023 06:00:01 بحسب Nasdaq GlobeNewswire

Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy

23 أبريل 2023 17:05:00 بحسب Nasdaq GlobeNewswire

Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

21 أبريل 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign

17 أبريل 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 أبريل 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 مارس 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

01 مارس 2023 06:00:02 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

27 فبراير 2023 16:19:35 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

22 فبراير 2023 20:48:09 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

22 فبراير 2023 06:22:35 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

21 فبراير 2023 15:14:10 بحسب Nasdaq GlobeNewswire

FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness

17 فبراير 2023 15:06:06 بحسب Nasdaq GlobeNewswire